Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

2.50
Hdl Handle:
http://hdl.handle.net/10541/75824
Title:
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
Authors:
Rowe, Jacob M; Buck, Georgina; Burnett, Alan K; Chopra, Rajesh; Wiernik, Peter H; Richards, Susan M; Lazarus, Hillard M; Franklin, Ian M; Litzow, Mark R; Ciobanu, Niculae; Prentice, H Grant; Durrant, I Jill; Tallman, Martin S; Goldstone, Anthony H
Abstract:
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved complete remission (CR). Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation; the others were randomly assigned to autologous transplantation or to consolidation/maintenance therapy for 2.5 years. Patients who did not achieve CR after induction had an overall survival rate of 5% compared with 45% for patients who achieved CR. Factors at diagnosis predictive of overall survival and disease-free survival were age (P = .001), white blood cell count less than 30 x 10(9)/L for B lineage or less than 100 x 10(9)/L for T lineage (P = .001) and immunophenotype, T lineage versus B lineage (P = .001). The data demonstrate that achieving CR with induction therapy is indispensable for long-term survival in adult patients with ALL. Furthermore, with a response rate greater than 90%, the induction regimen was highly efficacious as remission-inducing therapy. This large database has validated several previously identified independent prognostic factors in ALL, such as age, white blood cell count at presentation, cytogenetics, and immunophenotype. However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor.
Affiliation:
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel. rowe@jimmy.harvard.edu
Citation:
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. 2005, 106 (12):3760-7 Blood
Journal:
Blood
Issue Date:
1-Dec-2005
URI:
http://hdl.handle.net/10541/75824
DOI:
10.1182/blood-2005-04-1623
PubMed ID:
16105981
Type:
Article
Language:
en
ISSN:
0006-4971
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRowe, Jacob M-
dc.contributor.authorBuck, Georgina-
dc.contributor.authorBurnett, Alan K-
dc.contributor.authorChopra, Rajesh-
dc.contributor.authorWiernik, Peter H-
dc.contributor.authorRichards, Susan M-
dc.contributor.authorLazarus, Hillard M-
dc.contributor.authorFranklin, Ian M-
dc.contributor.authorLitzow, Mark R-
dc.contributor.authorCiobanu, Niculae-
dc.contributor.authorPrentice, H Grant-
dc.contributor.authorDurrant, I Jill-
dc.contributor.authorTallman, Martin S-
dc.contributor.authorGoldstone, Anthony H-
dc.date.accessioned2009-07-29T12:03:11Z-
dc.date.available2009-07-29T12:03:11Z-
dc.date.issued2005-12-01-
dc.identifier.citationInduction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. 2005, 106 (12):3760-7 Blooden
dc.identifier.issn0006-4971-
dc.identifier.pmid16105981-
dc.identifier.doi10.1182/blood-2005-04-1623-
dc.identifier.urihttp://hdl.handle.net/10541/75824-
dc.description.abstractThe international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved complete remission (CR). Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation; the others were randomly assigned to autologous transplantation or to consolidation/maintenance therapy for 2.5 years. Patients who did not achieve CR after induction had an overall survival rate of 5% compared with 45% for patients who achieved CR. Factors at diagnosis predictive of overall survival and disease-free survival were age (P = .001), white blood cell count less than 30 x 10(9)/L for B lineage or less than 100 x 10(9)/L for T lineage (P = .001) and immunophenotype, T lineage versus B lineage (P = .001). The data demonstrate that achieving CR with induction therapy is indispensable for long-term survival in adult patients with ALL. Furthermore, with a response rate greater than 90%, the induction regimen was highly efficacious as remission-inducing therapy. This large database has validated several previously identified independent prognostic factors in ALL, such as age, white blood cell count at presentation, cytogenetics, and immunophenotype. However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAge Factors-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshDisease-Free Survival-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPhiladelphia Chromosome-
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma-
dc.subject.meshPrognosis-
dc.subject.meshRemission Induction-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleInduction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel. rowe@jimmy.harvard.eduen
dc.identifier.journalBlooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.